Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging
暂无分享,去创建一个
Fabian Kiessling | Gunnar Brix | G. Brix | F. Kiessling | M. Jugold | Manfred Jugold | Eva C. Woenne
[1] M. Brechbiel,et al. 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent , 2001, Magnetic resonance in medicine.
[2] M V Knopp,et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] B. Rosen,et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results , 1996, Magnetic resonance in medicine.
[4] M. Neeman,et al. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. , 1999, Cancer research.
[5] M. Essig,et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[6] A. Ruddell,et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging of , 2008 .
[7] J. Folkman,et al. Angiogenesis Inhibitors: A New Class of Drugs , 2003, Cancer biology & therapy.
[8] A Heerschap,et al. Fast dynamic gadolinium‐enhanced MR imaging of urinary bladder and prostate cancer , 1999, Journal of magnetic resonance imaging : JMRI.
[9] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[10] B. Rosen,et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis , 1996, Magnetic resonance in medicine.
[11] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[12] L D Buadu,et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. , 1996, Radiology.
[13] M. Neeman,et al. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] P. Tofts,et al. Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.
[15] Michal Neeman,et al. In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice , 1999 .
[16] L. Schad,et al. Perfusionsmessung mit der T2*-Kontrastmitteldynamik in der Neuroonkologie , 2005, Der Radiologe.
[17] C K Kuhl,et al. Dynamic image interpretation of MRI of the breast , 2000, Journal of magnetic resonance imaging : JMRI.
[18] L R Schad,et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.
[19] H. Kauczor,et al. Dynamic contrast‐enhanced MRI for assessing the disease activity of multiple myeloma: A comparative study with histology and clinical markers , 2005, Journal of magnetic resonance imaging : JMRI.
[20] P. Vaupel,et al. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.
[21] M. Bock,et al. High‐resolution three‐dimensional MR angiography of rodent tumors: Morphologic characterization of intratumoral vasculature , 2003, Journal of magnetic resonance imaging : JMRI.
[22] J. Folkman,et al. Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.
[23] J. Capeau,et al. Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells , 1998, Gene Therapy.
[24] U. Vanhoefer,et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584 , 2003 .
[25] G Brix,et al. Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.
[26] G Brix,et al. Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.
[27] J. Folkman. Clinical Applications of Research on Angiogenesis , 1995 .
[28] James H Thrall,et al. Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.
[29] A. Padhani,et al. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging , 2005, Abdominal Imaging.
[30] H. Huisman,et al. Accurate estimation of pharmacokinetic contrast‐enhanced dynamic MRI parameters of the prostate , 2001, Journal of magnetic resonance imaging : JMRI.
[31] H. Schlemmer,et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004, European Radiology.
[32] N. van Bruggen,et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.
[33] S. Ogawa,et al. Oxygenation‐sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields , 1990, Magnetic resonance in medicine.
[34] Soonmee Cha,et al. Perfusion MR Imaging of Brain Tumors , 2004, Topics in magnetic resonance imaging : TMRI.
[35] C K Kuhl,et al. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. , 1997, Radiology.
[36] A. Padhani. MRI for assessing antivascular cancer treatments. , 2003, The British journal of radiology.
[37] R. Strecker,et al. Vessel size imaging in humans , 2005, Magnetic resonance in medicine.
[38] T. Sawyer. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors , 2004, Expert opinion on investigational drugs.
[39] P.-F. Liu,et al. MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging , 1998, European Radiology.
[40] Shelton D Caruthers,et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. , 2003, Circulation.
[41] D M Shames,et al. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries , 1998, Magnetic resonance in medicine.
[42] Peter Vaupel,et al. The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.
[43] P. Pasqualetti,et al. Enhancement patterns of prostate cancer in dynamic MRI , 2003, European Radiology.
[44] O. Haraldseth,et al. Differentiating Benign and Malignant Breast Lesions with T2*-Weighted First Pass Perfusion Imaging , 1999, Acta radiologica.
[45] R. Brasch,et al. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. , 2000, European journal of radiology.
[46] J. Folkman. Endogenous angiogenesis inhibitors , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[47] M. Neeman,et al. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. , 2002, Cancer research.
[48] L. Steinman,et al. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging , 2000, Journal of Neuroimmunology.
[49] Stasia A. Anderson,et al. Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .
[50] Siqing Shan,et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[51] Klaas Nicolay,et al. Lipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging , 2006, NMR in biomedicine.
[52] S A Wickline,et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. , 2000, Magnetic resonance in medicine.
[53] M. Neeman,et al. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: The role of stroma cells in tumor angiogenesis , 2005, International journal of cancer.
[54] G N Stewart,et al. Researches on the Circulation Time in Organs and on the Influences which affect it , 1893, The Journal of physiology.
[55] W. Kaiser,et al. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.
[56] Martin W. Brechbiel,et al. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. , 2003 .
[57] L R Schad,et al. High-resolution MR venography of cerebral arteriovenous malformations. , 1999, Magnetic resonance imaging.
[58] T. Ichikawa,et al. Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma. , 1999, AJR. American journal of roentgenology.
[59] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[60] K. Zierler,et al. On the theory of the indicator-dilution method for measurement of blood flow and volume. , 1954, Journal of applied physiology.
[61] J. Glökler,et al. Application of aptamers in therapeutics and for small-molecule detection. , 2006, Handbook of experimental pharmacology.
[62] Christopher M. Overall,et al. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.
[63] J. Folkman. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.
[64] T. Helbich,et al. Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition? , 2002, Academic radiology.
[65] Vasilis Ntziachristos,et al. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. , 2003, Radiology.
[66] L. Thoma,et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation , 2006, AAPS PharmSciTech.
[67] G. van Kaick,et al. Bone marrow microcirculation analysis in multiple myeloma by contrast‐enhanced dynamic magnetic resonance imaging , 2001, International journal of cancer.
[68] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[69] R L Ehman,et al. Intracranial aneurysms and vascular malformations: comparison of time-of-flight and phase-contrast MR angiography. , 1991, Radiology.
[70] A. Dennison,et al. Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention? , 2004, European journal of cancer.
[71] M. Bednarski,et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.
[72] Christopher M Overall,et al. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.
[73] Klaas Nicolay,et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[74] P. Turski,et al. Staging of arteriovenous malformations using three-dimensional time-of-flight MR angiography and volume-rendered displays of surface anatomy. , 1996, AJR. American journal of roentgenology.
[75] Michal Neeman,et al. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI , 2003, Nature Medicine.
[76] Wolfhard Semmler,et al. Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis , 2004, Nature Medicine.
[77] R. Brasch,et al. MRI monitoring of Avastin™ antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer , 2004, Journal of magnetic resonance imaging : JMRI.
[78] Robert C Brasch,et al. Imaging of tumor angiogenesis: current approaches and future prospects. , 2006, Current pharmaceutical design.
[79] Rakesh K Jain,et al. Molecular regulation of vessel maturation , 2003, Nature Medicine.
[80] M. Bock,et al. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. , 2006, Bioconjugate chemistry.
[81] Viktor Novikov,et al. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights , 2004, Journal of magnetic resonance imaging : JMRI.
[82] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[83] Ralph Weissleder,et al. Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer , 2006, Laboratory Investigation.
[84] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[85] Wolfhard Semmler,et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. , 2004, Neoplasia.
[86] C. Kuhl,et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.
[87] R. Lucht,et al. Microcirculation and microvasculature in breast tumors: Pharmacokinetic analysis of dynamic MR image series , 2004, Magnetic resonance in medicine.
[88] R. Brasch,et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. , 2002, Academic radiology.
[89] Wolfhard Semmler,et al. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI , 2004, European Radiology.
[90] L. Tei,et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. , 2006, Cancer research.
[91] L R Schad,et al. [Perfusion measurement using the T2* contrast media dynamics in neuro-oncology. Physical basics and clinical applications]. , 2005, Der Radiologe.
[92] Tom Mikkelsen,et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial , 2004, Journal of magnetic resonance imaging : JMRI.
[93] Samuel A. Wickline,et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .
[94] M. Décorps,et al. Vessel size imaging , 2001, Magnetic resonance in medicine.
[95] Y Usson,et al. In vivo assessment of tumoral angiogenesis , 2004, Magnetic resonance in medicine.
[96] G Brix,et al. Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. , 1998, Cancer research.
[97] D B Kopans,et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. , 1997, Radiology.